Patients Will Save Rs 4,450 Crore After Stent Price Cap: Govt

Here’s a roundup of the top stories of the day. 

The price control of stents will result in annual savings of about Rs 4,450 crore for patients, Parliament was informed on Tuesday.

Minister of State for Chemicals Mansukh L Mandaviya said in a written reply to the Lok Sabha:

After the inclusion of coronary stents in the Schedule I of DPCO 2013 on 21 December 2016, the prices were fixed by the NPPA on 12 February 2017, which will result in approximate annual savings of about Rs 4,450 crore to patients.

The National Pharmaceutical Pricing Authority (NPPA) had notified the ceiling price of coronary stents at Rs 7,260 for bare metal stent and Rs 29,600 for drug-eluting ones.

The corresponding average MRPs before the notification stood at Rs 45,100 and Rs 1.21 lakh.

Also Read: Hospitals or Dealers: Who’s Pocketing Margins on Medical Devices?

Mansukh L Mandaviya, Minister of State for ChemicalsPrice regulation has brought down the prices of bare metal stent by 74 percent and that drug-eluting stents by 85 percent.

In a separate reply, the minister said the NPPA has directed hospitals to issue detailed bills to patients, specifically and separately mentioning cost of the coronary stents along with brand name of manufacturer or importer and other details.

Also Read: Meet the Man Who Stands Against Making Unfair Bucks in Healthcare

Non-adherence to the rules will be treated as deliberate distortion of evidence along with charges of overpricing inviting prosecution under the Essential Commodities Act, Mandaviya added.

The government has alerted the states and state drug controllers to monitor the availability of stents, he said.

Mansukh L Mandaviya, Minister of State for ChemicalsIndustry has been apprised that all manufacturers, importers are under legal obligation to maintain smooth production and supply of coronary stents of all brands which were available in the country before price cap.

Also Read: Govt Caps Stent Prices, Patients Caught In the Nexus of Corruption

The NPPA already has conducted two rounds of discussions with the stent companies which in turn have promised required level of availability.